- The World Health Organization (WHO) has prequalified CERVAVAC, India's first indigenous quadrivalent human papillomavirus (qHPV) vaccine developed by the Serum Institute of India (SII). - CERVAVAC is designed to protect against cervical cancer caused by specific strains of the Human Papillomavirus (HPV), primarily HPV types 16, 18, 6, and 11. - WHO prequalification allows international organizations like UNICEF and GAVI to procure the vaccine for global immunization programs, enhancing access and affordability in low- and middle-income countries. - This milestone highlights India's growing capability in biopharmaceutical research, indigenous vaccine manufacturing, and global public health leadership. - **CERVAVAC:** India's first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine, created by the Serum Institute of India to prevent cervical and other HPV-related cancers. - **WHO Prequalification:** A rigorous quality, safety, and efficacy assessment system operated by the UN health agency that enables international procurement agencies like UNICEF to acquire vaccines for developing nations. - **Serum Institute of India:** The world's largest vaccine manufacturer by volume, based in Pune, India, known for producing affordable life-saving immunizations for global public health. **Introduction** The World Health Organization (WHO) has granted prequalification to CERVAVAC, a quadrivalent human papillomavirus (qHPV) vaccine developed indigenously by the Serum Institute of India (SII). Designed to prevent cervical cancer and other HPV-related diseases, this WHO prequalification enables global procurement agencies such as UNICEF and GAVI to supply the vaccine to low- and middle-income countries. The development underscores India's prowess in affordable vaccine manufacturing, biotechnology innovation, and its critical role in international public health security. **Core Issue and Detailed Points** - The World Health Organization (WHO) has prequalified CERVAVAC, India's first indigenous quadrivalent human papillomavirus (qHPV) vaccine developed by the Serum Institute of India (SII). - CERVAVAC is designed to protect against cervical cancer caused by specific strains of the Human Papillomavirus (HPV), primarily HPV types 16, 18, 6, and 11. - WHO prequalification allows international organizations like UNICEF and GAVI to procure the vaccine for global immunization programs, enhancing access and affordability in low- and middle-income countries. - This milestone highlights India's growing capability in biopharmaceutical research, indigenous vaccine manufacturing, and global public health leadership. **Key Statutory Bodies, Acts & Concepts** - **CERVAVAC:** India's first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine, created by the Serum Institute of India to prevent cervical and other HPV-related cancers. - **WHO Prequalification:** A rigorous quality, safety, and efficacy assessment system operated by the UN health agency that enables international procurement agencies like UNICEF to acquire vaccines for developing nations. - **Serum Institute of India:** The world's largest vaccine manufacturer by volume, based in Pune, India, known for producing affordable life-saving immunizations for global public health.